Study on the efficiency of dexmedetomidine in endobronchial ultrasound-guided transbronchial needle aspiration

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047902

Enrollment

Unknown

Registered

2021-06-27

Start date

2021-04-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adjunct anesthetic drug

Interventions

control group:no intervention

dexmedetomidine group:Pretreatment of single-dose Dexmedetomindine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.an American Society of Anesthesiologists (ASA) physical status I–III, and were between 18 and 75 years of age 2.body mass index =93% in air; SBP>=90mmHg and DBP>=55mmHg. 4.making full sense of the procedure of the study and complying with the clinical protocols.

Exclusion criteria

Exclusion criteria: 1.patient with anesthesia contraindication or history of anesthetic accident 2.patient with endotracheal intubation or mechanical ventilation 3. history of cardiovascular disease:severe arrhythmia, heart failure, adams-stokes syndrome, NYHA >=III, severe superior vena cana syndrome, unstable angina or recent myocardial infarction (within the past 6 months); tachycardia or bradycardia under treatment; advanced heart block (unless the patient had a pacemaker) 4.history of cardiovascular disease: severe COPD; acute attack of chronic lung disease; airway stenosis; larynx tumor; tracheoesophageal fistula; severe respiratory tract infection (within the past 2 weeks) 5.history of neuropsychiatric: craniocerebral injury; convulsions; intracranial hypertension; cerebral aneurysm; stroke; schizophrenia; mania; cognitive disorder; mental disease undertreatment 6.risk of airway management: acute attack of asthma; sleep apnea syndrome; history of malignant fever and failure of trachea cannula; possibility of difficult airway 7.history of gastrointestinal disease: gastric retention; active hemorrhage; gastroesophageal reflux 8.severe hepatic renal insufficiency

Design outcomes

Primary

Measure	Time frame
respiratory events;cardiovascular events;	—

Secondary

Measure	Time frame
satisfaction of operator and patients;	—

Countries

China

Contacts

Public ContactWANG LIANGRONG

The First Affiliated Hospital of Wenzhou Medical University

arerong1984@126.com13587884540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026